<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>363</serviceExecutionTime><Drug id="53461"><DrugName>QAX-935</DrugName><DrugSynonyms><Name><Value>HYB-2093</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>immunomodulatory oligonucleotide (asthma/allergy), Hybridon</Value></Name><Name><Value>IMO (asthma/allergy), Hybridon</Value></Name><Name><Value>immunomodulatory oligonucleotide (asthma/allergy), Idera</Value></Name><Name><Value>IMO (asthma/allergy), Idera</Value></Name><Name><Value>immunomodulatory oligonucleotides (asthma/allergy), Idera/Novartis</Value></Name><Name><Value>QAX-935</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IMO-2134</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17006">Idera Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="17006">Idera Pharmaceuticals Inc</Company><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="53461" type="Drug"><TargetEntity id="637638" type="siDrug">IMO-2134</TargetEntity></SourceEntity><SourceEntity id="17006" type="Company"><TargetEntity id="4295906738" type="organizationId">Idera Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="12" type="ciIndication"><TargetEntity id="10001708" type="MEDDRA"></TargetEntity><TargetEntity id="1180" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="7827" type="Action"><TargetEntity id="1782" type="Mechanism">Toll-Like Receptor 9 (TLR9) Agonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1747" type="Action"><TargetEntity id="1112" type="Mechanism">Immunoglobulin E (IgE) Production Inhibitors</TargetEntity><TargetEntity id="3700" type="Mechanism">Anti-IgE</TargetEntity><TargetEntity id="4322" type="Mechanism">Anti-IgE (Fc Region)</TargetEntity></SourceEntity><SourceEntity id="PTGT-01872" type="ciTarget"><TargetEntity id="1910496085541063" type="siTarget">Toll-like receptor 9</TargetEntity><TargetEntity id="8155" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="12">Allergy</Indication><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="1747">Immunoglobulin E antagonist</Action><Action id="7827">TLR-9 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="103">Oligonucleotide</Technology></Technologies><LastModificationDate>2017-08-22T09:05:56.000Z</LastModificationDate><ChangeDateLast>2014-06-19T00:00:00.000Z</ChangeDateLast><AddedDate>2005-06-23T13:39:33.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17006" linkType="Company"&gt;Idera Pharmaceuticals&lt;/ulink&gt; (formerly Hybridon) was developing QAX-935 (IMO-2134), the lead from a series of immunomodulatory oligonucleotide  (IMO) candidates, including  HYB-2093, that act through TLR-9 to downregulate Th2 immune responses including immunoglobulin E production, for the potential treatment of asthma and allergy  [&lt;ulink linkID="219076" linkType="Reference"&gt;219076&lt;/ulink&gt;], [&lt;ulink linkID="609085" linkType="Reference"&gt;609085&lt;/ulink&gt;], [&lt;ulink linkID="609088" linkType="Reference"&gt;609088&lt;/ulink&gt;]. In September 2008, a phase I study was initiated [&lt;ulink linkID="939775" linkType="Reference"&gt;939775&lt;/ulink&gt;]. In March 2011, Idera was evaluating the next steps for the development of the drug [&lt;ulink linkID="1175162" linkType="Reference"&gt;1175162&lt;/ulink&gt;].  In March 2012, the company was seeking to outlicense the program [&lt;ulink linkID="1271706" linkType="Reference"&gt;1271706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Idera is also developing IMOs for the treatment of cancer and infectious diseases, including &lt;ulink linkID="13279" linkType="Drug"&gt;IMO-2055&lt;/ulink&gt;. &lt;/para&gt;&lt;para&gt;Idera was previously developing the drug in collaboration with &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; [&lt;ulink linkID="219076" linkType="Reference"&gt;219076&lt;/ulink&gt;], [&lt;ulink linkID="609085" linkType="Reference"&gt;609085&lt;/ulink&gt;], [&lt;ulink linkID="609088" linkType="Reference"&gt;609088&lt;/ulink&gt;]. In November 2009, it was reported that Novartis would terminate its development of the drug as of  February 21, 2010 [&lt;ulink linkID="1060327" linkType="Reference"&gt;1060327&lt;/ulink&gt;]. The deal was terminated in February 2010 and all rights were returned to Idera [&lt;ulink linkID="1081222" linkType="Reference"&gt;1081222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2004, data were presented at the American College of Allergy, Asthma, &amp;amp; Immunology meeting in Boston, MA, showing that IMO DNA suppresses Th2 immune responses in an OVA-sensitized mouse lung, and induces potent Th1 immune responses and decreased OVA-induced allergic airway inflammation and airway hyperresponsiveness in a mouse model of established asthma [&lt;ulink linkID="570902" linkType="Reference"&gt;570902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, Hybridon presented preclinical data. Mice with established allergic asthmatic response to ovalbumin and treated with IMOs showed significantly improved lung function, compared with untreated animals. IMO treatment also resulted in significant reduction in bronchoalveolar lavage (BAL) and peribronchial eosinophilia, BAL and serum IL-5, and total serum IgE in asthmatic mice. Both IMO agents produced effects consistent with induction of a Th1 immune response [&lt;ulink linkID="528469" linkType="reference"&gt;528469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003, Hybridon presented preclinical data from studies of its second-generation IMOs in mouse models of allergic asthma. Co-administration of IMO compounds, containing either natural CpG or synthetic CpR motifs, to mice during ovalbumin (OVA) sensitization abrogated both early and late stage OVA-induced allergic responses, and blocked airway hyperresponsiveness. Additionally, co-administration of IMO compounds to mice with OVA-sensitization resulted in complete suppression of bronchoalveolar lavage fluid (BALF) eosinophilia, with concomitant decrease in the levels of Th-2 cytokines IL-4, IL-5, and IL-6 in both serum and BALF fluid, and a decrease in serum IgE [&lt;ulink linkID="504597" linkType="reference"&gt;504597&lt;/ulink&gt;]. Similar results were presented in the same month at the 18th Congress of the World Allergy Organization/International Association of Allergology and Clinical Immunology in Vancouver, Canada [&lt;ulink linkID="510112" linkType="reference"&gt;510112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2003, Hybridon presented preclinical studies of the use of its IMOs in allergic asthma models at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology in Denver, CO. The study evaluated several of Hybridon's proprietary IMO compounds containing novel immunomers and containing either a natural or synthetic CpG motif. In cells treated with a model antigen conalbumin (CA), the IMO compounds suppressed Th2-type cytokines and induced Th1-type cytokines. Two of the immunomers containing a natural phosphodiester backbone were further studied in in vivo mouse models of allergic asthma. Systemic administration of both immunomers significantly reduced CA-induced airway hyper-responsiveness and eosinophil count. In addition, in the in vivo studies, treatment with immunomers resulted in a significant increase in IFN-gamma secretion with concomitant reduction in CA-specific IgE antibody response and IL-5 secretion [&lt;ulink linkID="481557" linkType="reference"&gt;481557&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2005, Hybridon and Novartis were collaborating on the evaluation of novel IMO candidates which Novartis would then have the option of developing  and commercializing. Novartis would pay Idera fees based on the development progress and sales of candidates [&lt;ulink linkID="604912" linkType="Reference"&gt;604912&lt;/ulink&gt;], [&lt;ulink linkID="622975" linkType="Reference"&gt;622975&lt;/ulink&gt;], [&lt;ulink linkID="1060327" linkType="Reference"&gt;1060327&lt;/ulink&gt;]. In March 2007, Idera  and Novartis extended their R&amp;amp;D collaboration by one year [&lt;ulink linkID="771305" linkType="Reference"&gt;771305&lt;/ulink&gt;]. In September 2008, Idera received a milestone payment triggered by the start of phase I studies [&lt;ulink linkID="939775" linkType="Reference"&gt;939775&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1996, Hybridon sponsored research programs with the &lt;ulink linkID="17237" linkType="Company"&gt;Institut Pasteur&lt;/ulink&gt;, &lt;ulink linkID="21081" linkType="Company"&gt;Institut Gustave Roussy&lt;/ulink&gt; and the Norwegian Radium Hospital to develop therapeutic oligonucleotides [&lt;ulink linkID="219076" linkType="reference"&gt;219076&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2010-02-28T00:00:00.000Z</StatusDate><Source id="1081222" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="12">Allergy</Indication><StatusDate>2010-02-28T00:00:00.000Z</StatusDate><Source id="1081222" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2014-04-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2014-04-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2008-09-02T00:00:00.000Z</StatusDate><Source id="939775" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2008-09-02T00:00:00.000Z</StatusDate><Source id="939775" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>1996-09-09T00:00:00.000Z</StatusDate><Source id="609085" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17006">Idera Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1996-09-09T00:00:00.000Z</StatusDate><Source id="609085" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2005-09-14T00:00:00.000Z</StatusDate><Source id="622975" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2005-09-14T00:00:00.000Z</StatusDate><Source id="622975" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="12">Allergy</Indication><StatusDate>2008-09-02T00:00:00.000Z</StatusDate><Source id="939775" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2008-09-02T00:00:00.000Z</StatusDate><Source id="939775" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01006"><Name>Immunoglobulin E</Name><SwissprotNumbers/></Target><Target id="PTGT-01872"><Name>TLR-9</Name><SwissprotNumbers><Swissprot>Q9EQU3</Swissprot><Swissprot>Q9NR96</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17006">Idera Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17237">Institut Pasteur</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="108226" title="Novartis to develop Idera's TLR9-targeting candidates for asthma and allergy  "/><Deal id="117092" title="Hybridon and Institut Pasteur to develop therapeutic oligonucleotides "/></Deals><PatentFamilies><PatentFamily id="1484688" number="WO-2010088395" title="Novel synthetic agonists of TLR9"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Idera Pharmaceuticals Inc" id="17006"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>